Press Release: DermBiont : DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting

BOSTON--(BUSINESS WIRE)--DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of a variety of dermatological indications, today announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician's lesion assessment (PLA) score at last visit and safety via local tolerability, as well as key multiple secondary endpoints including complete clear